Moreover, PD-L2 blocking on RPMI8226 cells significantly improved the expanded NK cell-mediated suppression of tumor growth and prolonged the survival of myeloma mice, suggesting that adoptive NK cell therapy combined with in vitro or in vivo PD1/PD-ligand blocking may have a great clinical potential for cancers. This evidence concerns the gene PDCD1LG2 and plasma cell myeloma.